title: Evaluation of the effect of endothelin-1 and characterization of the selective endothelin a receptor antagonist PD155080 in the prostate.
abstract: OBJECTIVE
  To evaluate the contractile effect of endothelin-1 (ET-1) on prostatic urethral pressure and to characterize the effect of the selective ETA receptor antagonist PD155080 on ET-1 mediated prostatic urethral pressure.
  
  
  METHODS
  The effect of intravenous ET-1 administration on canine urethral pressure was determined in the presence and absence of PD155080. The affinity of PD155080 for endothelin-mediated contraction was determined using antagonist dissociation studies. Saturation and competition binding studies were performed using [125I] ET-1 in both human and canine prostate.
  
  
  RESULTS
  ET-1 bolus injection elicited shallow and prolonged increases the prostatic urethral pressure. Pretreatment with PD155080 totally abolished the urethral contractile response to ET-1. Specific [125I] ET-1 binding was saturable and of high affinity. Two ET receptor subtypes (ETA receptor, ETB receptor) have been identified in human prostate. The ratio of ETA to ETB receptors was approximately 1.5:1 in both human and canine prostates. Isometric tension studies revealed that PD155080 shifted the ET-1 dose-response curves to the right and exhibited no effect on the ETB receptor selective agonist sarafotoxin dose-response curves.
  
  
  CONCLUSIONS
  ET-1 mediates prostate smooth muscle tone and may play a role in the pathophysiology and treatment of benign prostatic hyperplasia (BPH).
authors.affiliation: Department of Urology, Biochemistry and Pharmacology, New York University Medical Center, New York 10016, USA.
authors.forename: C
authors.initials: C
authors.lastname: Imajo
authors.forename: P D
authors.initials: PD
authors.lastname: Walden
authors.forename: E
authors.initials: E
authors.lastname: Shapiro
authors.forename: A M
authors.initials: AM
authors.lastname: Doherty
authors.forename: H
authors.initials: H
authors.lastname: Lepor
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D004149:Dioxoles / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects*; D010456:Peptides, Cyclic / Q000494:pharmacology; D011312:Pressure; D011467:Prostate / Q000187:drug effects* / Q000502:physiology; D014521:Urethra / Q000187:drug effects* / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014757:Viper Venoms / Q000494:pharmacology
chemical_list: D004149:Dioxoles; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; C093322:PD 155080; D010456:Peptides, Cyclic; D014662:Vasoconstrictor Agents; D014757:Viper Venoms; C057354:sarafotoxins s6; C072247:cyclo(Trp-Asp-Pro-Val-Leu)